Blockbuster Biologic Enbrel Will Continue As A Monopoly For Another 8 Years The FDA has accelerated the approval process for generics and biosimilars, which has resulted in a slew of biosimilar approvals. But that’s a necessary, not a sufficient condition for biosimilar market entry. Protracted patent battles have delayed the launch of many high-profile biosimilars.